Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Abraham Ceesay Sells 2,210 Shares

October 24, 2026 by InsiderTrades.com

Key Points

CEO Abraham Ceesay sold 2,210 shares at an average price of $29.16, generating $64,443.60; he still directly owns 450,035 shares, with the sale reducing his stake by 0.49%.
Analysts remain broadly bullish, with the stock carrying an average “Buy” rating and a consensus price target of $68.36; UBS initiated coverage with a $71 target, while BTIG raised its target to $89.
Rapport remains an unprofitable clinical-stage biotech: it reported quarterly EPS of -$1.19, missing estimates of -$1.12, and analysts expect a full-year loss of roughly $4.08 per share.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of the business's stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $29.16, for a total value of $64,443.60. Following the sale, the chief executive officer directly owned 450,035 shares of the company's stock, valued at $13,123,020.60. This represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Abraham Ceesay also recently made the following trade(s):

On Wednesday, October 7th, Abraham Ceesay sold 1,147 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.66, for a total transaction of $35,167.02.
On Tuesday, October 6th, Abraham Ceesay sold 3,375 shares of Rapport Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $108,101.25.
On Wednesday, September 23rd, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $39.17, for a total transaction of $86,565.70.
On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $45.61, for a total transaction of $374,458.10.
On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The stock was sold at an average price of $49.57, for a total transaction of $937,913.97.
On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58.
On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total transaction of $1,042,746.66.
On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP opened at $25.93 on Friday. Rapport Therapeutics, Inc. has a fifty-two week low of $23.75 and a fifty-two week high of $52.93. The firm has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.22. The company's 50 day simple moving average is $39.01 and its 200 day simple moving average is $38.93.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). Sell-side analysts expect that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Analyst Ratings Changes

RAPP has been the topic of several recent research reports. TD Cowen restated a "buy" rating on shares of Rapport Therapeutics in a research report on Tuesday. UBS Group began coverage on Rapport Therapeutics in a research note on Thursday, October 15th. They set a "buy" rating and a $71.00 price objective for the company. BTIG Research upped their price objective on Rapport Therapeutics from $75.00 to $89.00 and gave the company a "buy" rating in a report on Tuesday. Citigroup reissued an "outperform" rating on shares of Rapport Therapeutics in a research note on Tuesday. Finally, Wolfe Research began coverage on Rapport Therapeutics in a report on Thursday, October 15th. They set an "outperform" rating and a $50.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $68.36.

Get Our Latest Research Report on Rapport Therapeutics

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. AlphaCentric Advisors LLC increased its stake in Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company's stock valued at $201,000 after purchasing an additional 408 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Rapport Therapeutics by 597.9% in the third quarter. Sterling Capital Management LLC now owns 984 shares of the company's stock worth $33,000 after purchasing an additional 843 shares during the period. KBC Group NV acquired a new stake in Rapport Therapeutics in the first quarter worth $30,000. State of Wyoming acquired a new stake in Rapport Therapeutics in the second quarter worth $65,000. Finally, Swiss National Bank boosted its position in shares of Rapport Therapeutics by 3.5% during the first quarter. Swiss National Bank now owns 56,500 shares of the company's stock worth $1,768,000 after purchasing an additional 1,900 shares in the last quarter.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.